PCSK9 Enhances Platelet Activation, Thrombosis, and Myocardial Infarct Expansion by Binding to Platelet CD36
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PCSK9 Enhances Platelet Activation, Thrombosis, and Myocardial Infarct Expansion by Binding to Platelet CD36
Authors
Keywords
-
Journal
CIRCULATION
Volume -, Issue -, Pages -
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2020-09-29
DOI
10.1161/circulationaha.120.046290
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials
- (2019) Paul Guedeney et al. EUROPEAN HEART JOURNAL
- PCSK9 expression in the ischaemic heart and its relationship to infarct size, cardiac function, and development of autophagy
- (2018) Zufeng Ding et al. CARDIOVASCULAR RESEARCH
- Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor
- (2018) Sreeneeranj Kasichayanula et al. CLINICAL PHARMACOKINETICS
- PCSK9 as a Positive Modulator of Platelet Activation
- (2018) Marina Camera et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- OUP accepted manuscript
- (2018) NEPHROLOGY DIALYSIS TRANSPLANTATION
- PCSK9: A novel inflammation modulator in atherosclerosis?
- (2018) Zhi-Han Tang et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
- (2018) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: The PCSK9-REACT study
- (2017) Eliano P. Navarese et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Exploration of PCSK9 as a Cardiovascular Risk Factor
- (2017) Paul A. Gurbel et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Relationship of PCSK9 and Urinary Thromboxane Excretion to Cardiovascular Events in Patients With Atrial Fibrillation
- (2017) Daniele Pastori et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Proprotein convertase subtilisin/kexin type 9 (PCSK9) Deficiency is Protective Against Venous Thrombosis in Mice
- (2017) Hui Wang et al. Scientific Reports
- Mortality Differences Associated With Treatment Responses in CANTOS and FOURIER
- (2017) Paul M Ridker CIRCULATION
- Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome
- (2016) Eliano P. Navarese et al. ANNALS OF INTERNAL MEDICINE
- Ask1 regulates murine platelet granule secretion, thromboxane A2generation, and thrombus formation
- (2016) Meghna U. Naik et al. BLOOD
- Pleiotropic Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors?
- (2016) Vera Bittner CIRCULATION
- Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Predicts Future Risk of Cardiovascular Events Independently of Established Risk FactorsCLINICAL PERSPECTIVE
- (2016) Karin Leander et al. CIRCULATION
- Platelet-Mediated Thrombosis
- (2016) Paul A. Gurbel et al. CIRCULATION RESEARCH
- Disordered haematopoiesis and athero-thrombosis
- (2016) Andrew J. Murphy et al. EUROPEAN HEART JOURNAL
- Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions
- (2016) Michael G. Silverman et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Hypoxic mitophagy regulates mitochondrial quality and platelet activation and determines severity of I/R heart injury
- (2016) Weilin Zhang et al. eLife
- PCSK9 Induces CD36 Degradation and Affects Long-Chain Fatty Acid Uptake and Triglyceride Metabolism in Adipocytes and in Mouse LiverSignificance
- (2015) Annie Demers et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Oxidized LDL activates blood platelets through CD36/NOX2-mediated inhibition of the cGMP/protein kinase G signaling cascade
- (2015) S. Magwenzi et al. BLOOD
- Platelet Extracellular Regulated Protein Kinase 5 Is a Redox Switch and Triggers Maladaptive Platelet Responses and Myocardial Infarct ExpansionCLINICAL PERSPECTIVES
- (2015) Scott J. Cameron et al. CIRCULATION
- Nucleotide-Binding Oligomerization Domain 2 Receptor Is Expressed in Platelets and Enhances Platelet Activation and ThrombosisCLINICAL PERSPECTIVE
- (2015) Si Zhang et al. CIRCULATION
- Plasma proprotein convertase subtilisin/kexin type 9 levels and the risk of first cardiovascular events
- (2015) Paul M. Ridker et al. EUROPEAN HEART JOURNAL
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
- (2015) Jennifer G. Robinson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Platelet-derived S100 family member myeloid-related protein-14 regulates thrombosis
- (2014) Yunmei Wang et al. JOURNAL OF CLINICAL INVESTIGATION
- PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE
- (2014) Brandon Ason et al. JOURNAL OF LIPID RESEARCH
- Risk prediction with proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment
- (2014) Christian Werner et al. VASCULAR PHARMACOLOGY
- PCSK9 plays a significant role in cholesterol homeostasis and lipid transport in intestinal epithelial cells
- (2013) Emile Levy et al. ATHEROSCLEROSIS
- Serum Proprotein Convertase Subtilisin/Kexin Type 9 and Cell Surface Low-Density Lipoprotein Receptor
- (2013) Hagai Tavori et al. CIRCULATION
- Multimolecular Signaling Complexes Enable Syk-Mediated Signaling of CD36 Internalization
- (2013) Bryan Heit et al. DEVELOPMENTAL CELL
- Targeting the Proprotein Convertase Subtilisin/Kexin Type 9 for the Treatment of Dyslipidemia and Atherosclerosis
- (2013) Daniel Urban et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- A directional switch of integrin signalling and a new anti-thrombotic strategy
- (2013) Bo Shen et al. NATURE
- Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Can Mediate Degradation of the Low Density Lipoprotein Receptor-Related Protein 1 (LRP-1)
- (2013) Maryssa Canuel et al. PLoS One
- Advanced glycation end products induce a prothrombotic phenotype in mice via interaction with platelet CD36
- (2012) W. Zhu et al. BLOOD
- P2Y12protects platelets from apoptosis via PI3k-dependent Bak/Bax inactivation
- (2012) S. ZHANG et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- The disulfide isomerase ERp57 mediates platelet aggregation, hemostasis, and thrombosis
- (2011) Y. Wu et al. BLOOD
- Platelet CD36 surface expression levels affect functional responses to oxidized LDL and are associated with inheritance of specific genetic polymorphisms
- (2011) A. Ghosh et al. BLOOD
- Diabetes and Antiplatelet Therapy in Acute Coronary Syndrome
- (2011) José Luis Ferreiro et al. CIRCULATION
- Signaling During Platelet Adhesion and Activation
- (2010) Zhenyu Li et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- A platelet tetraspanin superfamily member, CD151, is required for regulation of thrombus growth and stabilityin vivo
- (2009) E. ORLOWSKI et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Mechanisms of platelet activation: Need for new strategies to protect against platelet-mediated atherothrombosis
- (2009) Lisa Jennings THROMBOSIS AND HAEMOSTASIS
- Microvascular Obstruction and the No-Reflow Phenomenon After Percutaneous Coronary Intervention
- (2008) Ronen Jaffe et al. CIRCULATION
- A Specific CD36-Dependent Signaling Pathway Is Required for Platelet Activation by Oxidized Low-Density Lipoprotein
- (2008) Kan Chen et al. CIRCULATION RESEARCH
- Plasma PCSK9 preferentially reduces liver LDL receptors in mice
- (2008) Aldo Grefhorst et al. JOURNAL OF LIPID RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started